<DOC>
	<DOCNO>NCT00373204</DOCNO>
	<brief_summary>The purpose study determine addition motexafin gadolinium ( study drug ) standard treatment docetaxel improve response rate patient non-small cell lung cancer .</brief_summary>
	<brief_title>Study Effect Non-small Cell Lung Cancer Investigational Drug Motexafin Gadolinium When Used Combination With Docetaxel ( Taxotere )</brief_title>
	<detailed_description>Preclinical clinical data suggest MGd activity NSCLC combination MGd docetaxel may effective docetaxel alone . In trial , patient receive 10 mg/kg MGd follow 75 mg/m2 every 3 week . This dose regimen well tolerated Phase I dose escalation trial . A Simon 2-stage trial design use ; least 4 39 evaluable patient first stage trial demonstrate objective clinical response , study proceed Stage 2 , additional 22 evaluable patient enrol follow treatment regimen assessment schedule Stage 1 . Patients stable disease , CR , PR continue dose 12 cycle follow response every 6 week PD , death , end study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<criteria>≥ 18 year old Histologically cytologically confirm diagnosis NSCLC Inoperable Stage IIIA , unresectable Stage IIIB metastatic NSCLC patient receive 1 prior platinumbased chemotherapy regimen Measurable disease per RECIST ECOG performance status score 0 1 Willing able provide write informed consent Laboratory value : ANC &lt; 1500/mm³ , Platelet count &lt; 100,000/mm³ , hemoglobin &lt; 10 g/dL , AST ALT &gt; 2.5 x upper limit normal ( ULN ) , Alkaline phosphatase &gt; 5 x ULN , bilirubin &gt; 1.5 x ULN , serum creatinine &gt; 2.0 mg/dL ( 176 umol/dL ) , albumin &lt; 3.0 g/dL ( 30 g/L ) Symptomatic uncontrolled ( untreated treat progressing ) brain metastasis Evidence meningeal metastasis &gt; 1 prior cytotoxic regimen ( count adjuvant neoadjuvant cytotoxic chemotherapy complete &gt; 12 month prior cytotoxic regimen , prior MGd ) Chemotherapy , radiation therapy , experimental therapy , immunotherapy , systemic biologic anticancer therapy within 21 day begin study treatment Significant weight loss ≥ 10 % body weight within precede 6 week Treatment another cancer within 3 year enrollment , except basal cell carcinoma skin cervical cancer situ Myocardial infarction within 6 month enrollment congestive heart failure rat New York Heart Association Class III IV Uncontrolled hypertension ( systolic blood pressure &gt; 160 mm Hg diastolic blood pressure &gt; 110 mm Hg maximal medical therapy ) Known history porphyria ( test require screening visit ) Known history glucose6phosphate dehydrogenase ( G6PD ) deficiency ( test require screening visit ) History hypersensitivity taxanes polysorbate 80 Known history HIV infection ( test require screening visit ) Female pregnant lactating ( serum pregnancy test require female patient childbearing potential ) Sexually active male female childbearing potential unwilling use adequate contraceptive protection Physical mental condition make patient unable complete specify followup assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Advanced non-small cell lung cancer</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Lung cancer</keyword>
	<keyword>Metastatic lung cancer</keyword>
	<keyword>Second line treatment advance lung cancer</keyword>
	<keyword>Cancer</keyword>
	<keyword>Advanced lung cancer</keyword>
</DOC>